Addressing Inflammation and Metabolic Issues: The Intracellular and Extracellular Dialogue
Saturday, September 16: 10:10AM - 11:10AM (1 CME credit hour)
 
ABOUT THE LECTURE:
The long-term presence of an inflammatory milieu is recognized as a fundamental force in the physiology of aging and the development of chronic degenerative, metabolic and autoimmune diseases. Research continues to reveal an exquisitely complex communication network at the intra- and inter- cellular levels. These signaling pathways are at the same time essential for homeostasis and, when dysregulated, the orchestrators of destructive downstream effects that translate into structural and functional damage at the cellular, tissue, organ and systemic levels. Therapeutic modulation of these signaling cascades is emerging as a new frontier in both integrative and conventional approaches to addressing chronic illness.

The phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) are highly interconnected signaling pathways (PI3K/AKT/mTOR) necessary for cell growth and survival, regulating many major cellular processes, and implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration. When glucose levels are high, insulin and therefore IGF are produced, activating the PI3K/AKT pathway which promotes proliferation. Dysregulation of the mTOR pathway tumor formation and angiogenesis, insulin resistance, adipogenesis and T-lymphocyte activation, promoting both cancer and Type 2 diabetes. Inhibition of mTOR is a subject of intense therapeutic interest, shown to have a major impact on cellular metabolism by stimulating synthesis of proteins and lipids, inhibiting catabolic processes, and controlling cell survival, lipogenesis, and gluconeogenesis.

Gal-3 is a protein increasingly studied for its causative role as an active biomarker and therapeutic target, an initiator of multiple signaling cascades via binding to glycoproteins and glycolipids within the cell, at the cell surface interface, interstitially and in the circulation. With over 3,000 publications to date, there is extensive clinical and preclinical support for the role of elevated Gal-3 in driving chronic inflammation, fibrosis of organs and tissues, cancer proliferation/metastasis, autoimmune and neurodegenerative disorders, and metabolic dysregulation characteristic of obesity and type 2 diabetes. Gal-3 inhibition is emerging as a highly promising and effective therapeutic target to address common roots of illness across this broad spectrum of conditions.

In this presentation, Dr. Eliaz will discuss the latest research on Gal-3 and PI3K/AKT/mTOR, and review in detail their regulatory functions, and the pathological consequences of dysregulation - becoming prime orchestrators of the epidemic degenerative diseases of our time. Current research on modulation of these pathways with targeted interventions, clinical case studies, and practice-based protocols will be shared.
 
ABOUT DR. ELIAZ:
Isaac Eliaz, MD, MS, LAc, has been in clinical practice for over 30 years with a focus on integrative approaches to complex chronic conditions and cancer. His activities include extensive research endeavors in collaboration with leading academic and research institutions, fostering translation of research into practical clinic tools. As a recognized expert in the role of galectin-3 in health and disease, Dr. Eliaz has coauthored numerous peer reviewed papers and is a frequent CME lecturer, sharing his research findings at international scientific conferences around the world. Dr. Eliaz also offers meditation and healing retreats to health care providers and patients with emphasis on personal healing as well as integrating insights and tools into one’s clinical practice.

DISCLOSURE STATEMENT
Dr. Eliaz has indicated that he has no financial relationships with any commercial supporters.

ISAAC ELIAZ, MD
 
 

NEED ASSISTANCE REGISTERING? A Meeting by Design
1.888.995.3088  |  info@ameetingbydesign.com

ACAM HEADQUARTERS: 
1.800.532.3688  |  info@acam.org  |  www.acam.org